Fig. 1: Study diagram, consort diagram, and response rate. | Blood Cancer Journal

Fig. 1: Study diagram, consort diagram, and response rate.

From: A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

Fig. 1

A Consort diagram. Not evaluable for response: aDid not receive mitoxantrone due to death (enterocolitis and sepsis, n = 1); bSuicide attempt prior to response assessment (n = 1) and acute decompensation due to septic shock prior to completion of cytarabine (n = 1); cDid not complete alvocidib cycle 1, day 2 due to TLS or day 3 due to tachycardia, tachypnea, hypotension, and worsening liver function tests. Patient eventually withdrew consent (n = 1). B Study diagram. C Response rates of alvocidib in combination with cytarabine and mitoxantrone in relapsed/refractory AML. Percentages within each column indicate response in that cohort. CRi CR with incomplete recovery, PR partial remission, MLFS morphologic leukemia-free state, NR no response, N/A no response assessment due to early death.

Back to article page